YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
Immunocore IMCR announced that it has achieved target enrollment of 540 patients in the phase III TEBE-AM study, which is evaluating its sole marketed drug, Kimmtrak (tebentafusp), in patients with second-line or later advanced melanoma. T…
Immunocore Holdings plc Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 20…
Immunocore Holdings plc Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercia…
Immunocore's IMCR sole marketed drug, Kimmtrak (tebentafusp-tebn), which is approved for treating patients with unresectable or metastatic uveal melanoma (mUM), has been witnessing strong demand. Currently, the company's top line solely co…
Immunocore Holdings plc IMCR has gained 21.2% over the past 12 weeks, putting the durability of that advance in focus. Kimmtrak demand and late-stage pipeline progress give investors concrete operating and clinical milestones to watch. The…
Immunocore Holdings plc IMCR offers a clear trade-off between commercial momentum and valuation risk. Kimmtrak continues to expand in metastatic uveal melanoma, while late-stage studies could open larger markets. The counterweight is equal…
Immunocore Holdings plc IMCR posted second-quarter 2026 revenues of $115.9 million, up 18.3% year over year and above the Zacks Consensus Estimate of $114 million. The company's loss of 2 cents per share, however, was wider than the consen…
Immunocore Holdings plc IMCR incurred a loss of 2 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 1 cent per share. In the year-ago quarter, the company had incurred a loss of 20 cents pe…
Shares of Immunocore Holdings PLC Sponsored ADR (IMCR) have gained 4.3% over the past four weeks to close the last trading session at $34.5, but there could still be a solid upside left in the stock if short-term price targets of Wall Stre…
Immunocore Holdings plc has reported past second-quarter 2026 results showing revenue of US$115.93 million, with net loss narrowing to US$0.808 million, while first-half 2026 revenue reached US$222.60 million and shifted from a prior-perio…
Earnings Call Insights: Immunocore Holdings plc (IMCR) Q2 2026 MANAGEMENT VIEW * Dr. Bahija Jallal (CEO & Executive Director) emphasized execution against three priorities: "maximizing the value of KIMMTRAK, advancing our melanoma portfoli…
Key Points Interested in Immunocore Holdings PLC Sponsored ADR? Here are five stocks we like better. KIMMTRAK sales continued to grow: First-half net sales reached $223 million, up 16% year over year, while second-quarter sales rose 18% to…
This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Kimtrak generated $223 million in net revenue in t…
This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Kimtrak generated $223 million in net revenue in t…
Immunocore Holdings plc Immunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM…
* Immunocore (IMCR [https://seekingalpha.com/symbol/IMCR]) is scheduled to announce Q2 earnings results on Thursday, August 6th, before market open. * The consensus EPS Estimate is $0.02 [https://seekingalpha.com/symbol/IMCR/earnings/estim…
Immunocore Holdings plc Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 30 July 2026) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore…
Immunocore Holdings IMCR is trying to move beyond the profile of a one-product rare-cancer company. Kimmtrak remains its commercial anchor, but the broader story is increasingly about the company's T-cell receptor platform. That shift matt…
Immunocore Holdings IMCR gives investors a mixed setup. Kimmtrak sales are still growing, the balance sheet is substantial and the pipeline has several value-creating shots on goal. The caution is concentration. All current revenues come f…
Immunocore Holdings IMCR has built its commercial base around Kimmtrak, its only marketed product and a standard treatment for eligible metastatic uveal melanoma patients in most launched markets. The investor question is whether deeper ad…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Immunocore Holdings (NasdaqGS:IMCR) has drawn fresh attention after a recent move in its share price, with the stock up around 21.6…
AbbVie ABBV announced that the European Commission (EC) approved the expanded use of Tepkinly (epcoritamab) for the relapsed or refractory follicular lymphoma (R/R FL) indication. The EC approved the drug in combination with rituximab and…
AtaiBeckley ATAI announced the completion of dosing the last patient in the phase IIb Elumina study evaluating VLS-01 for adults with treatment-resistant depression (TRD), marking an important operational milestone for the clinical program…
TG Therapeutics TGTX announced that it has initiated a phase II study evaluating Briumvi (ublituximab-xiiy) for the treatment of adult patients with treatment-resistant schizophrenia. Shares of the company were up 4.1% yesterday following…
Swiss pharma giant Novartis NVS announced an agreement to acquire privately held UK-based biotechnology company Myricx Bio, which is developing a novel class of antibody-drug conjugates (ADCs) utilizing N-myristoyltransferase inhibitor (NM…
Neurocrine Biosciences NBIX continues to strengthen its growth profile through the solid commercial performance of its marketed therapies, a steadily advancing late-stage neuroscience pipeline and strategic business development initiatives…
United Therapeutics UTHR announced the acquisition of Thymmune Therapeutics, a Cambridge-based privately held biotech company developing scalable, regenerative thymic cell therapies. The acquisition reinforces UTHR's commitment to advancin…
Novartis NVS obtained approval from the European Commission (EC) for Itvisma (onasemnogene abeparvovec) for the treatment of children two years and older, teens and adults living with 5q spinal muscular atrophy (SMA) with a bi-allelic muta…
Vertex Pharmaceuticals VRTX announced that the FDA has approved its one-shot gene therapy, Casgevy (exagamglogene autotemcel), for the treatment of individuals aged two years and older with either sickle cell disease (SCD) with recurrent v…
Catalyst Pharmaceuticals CPRX has reported positive top-line results from an early-stage study evaluating Agamree (vamorolone) to explore additional indications beyond its currently approved use in Duchenne muscular dystrophy (DMD) patient…
Pacira BioSciences PCRX has announced that UnitedHealthcare, the largest U.S. health insurer with about 40 million members, will reimburse separately for Exparel (bupivacaine liposome injectable suspension), Pacira's non-opioid pain medici…
Shares of Collegium Pharmaceutical COLL have gained around 12% over the past three months, driven by growing investor confidence in the company's expanding commercial portfolio, durable revenue base and long-term growth strategy. Jornay PM…
Shares of Viridian Therapeutics VRDN have gained 6.3% over the past week compared with the industry's 5.5% growth. The upside came after the company announced that the FDA approved veligrotug, an IGF-1R antagonist, under priority review fo…
Pacira BioSciences PCRX is reshaping its business through an agreement to divest its iovera medical device franchise to Zimmer Biomet ZBH for up to $140 million. The deal marks another step in Pacira's strategy to transition toward an inno…
Sanofi SNY announced that the phase III Baby-COMET study evaluating Nexviazyme (avalglucosidase alfa) in patients with infantile-onset Pompe disease (IOPD) has met all primary and secondary endpoints. The study met its primary endpoint by…